486 results
8-K
EX-99.1
MRK
Merck & Co Inc
25 Apr 24
Merck Announces First-Quarter 2024 Financial Results
6:41am
conjugate vaccine designed for adults. If approved, V116 would be the first pneumococcal conjugate vaccine designed to address the serotypes responsible
PX14A6G
r7svhz0yt
27 Mar 24
Letter to shareholders
8:57pm
S-3ASR
yv9o7zxg5u
19 Mar 24
Automatic shelf registration
4:28pm
S-3ASR
3bkb73mi0 pa
19 Mar 24
Automatic shelf registration
4:26pm